


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claim 1 (currently amended): An inhibitor of hexoaminidase or glycosidase represented by the following structure:



wherein:

R¹ is selected from the group consisting of hydrogen, sulfate, and methyl sulfate;

R² is selected from the group consisting of hydrogen, methyl, ethyl, and a branched or unbranched hydrocarbon having between 3 and 8 carbons; and

R³ is a hydrocarbon having between 1 and 50 carbon atoms;
with a proviso that R¹ and R² can not be hydrogen simultaneously.

Claim 2 (original): An inhibitor according to claim 1 wherein R¹ is hydrogen; R² is selected from the group consisting of hydrogen, methyl, ethyl, and a branched or unbranched hydrocarbon of between 3 and 8 carbon atoms; and R³ is a hydrocarbon having between 1 and 20 carbon atoms.

Claim 3 (original): An inhibitor according to claim 2 where R³ is a hydrocarbon having between 1 and 8 carbon atoms.

Claim 4 (original): An inhibitor according to claim 3 where R³ is methyl.

Claim 5 (original): An inhibitor according to claim 1 where R¹ is a sulfate group; R² is hydrogen, methyl, ethyl or any branched or unbranched hydrocarbon of between 3 and 8 carbon atoms; R³ is a hydrocarbon group that has between 1 and 20 carbon atoms.

Claim 6 (original): An inhibitor according to claim 5 where R³ is a hydrocarbon group possessing between 1 and 8 carbon atoms.


Claim 7 (original): An inhibitor according to claim 6 where R³ is methyl.

Claim 8 (original): An inhibitor according to claim 1 where R¹ is a methyl sulfate group; R² is selected from the group consisting of hydrogen, methyl, ethyl, and a branched or unbranched hydrocarbon of between 3 and 8 carbon atoms; R³ is a hydrocarbon having between 1 and 20 carbon atoms.

Claim 9 (original): An inhibitor according to claim 8 where R³ is a hydrocarbon having between 1 and 8 carbon atoms.

Claim 10 (original): An inhibitor according to claim 9 where R³ is methyl.

Claim 11 (original): An inhibitor of hexoaminidase or glycosidase represented by the following structure:



wherein:

R¹ is selected from the group consisting of hydrogen, sulfate, and methyl sulfate;

R² is selected from the group consisting of hydrogen, methyl, ethyl, and a branched or unbranched hydrocarbon having between 3 and 8 carbons; and

R³ is selected from the group consisting of hydroxyl and -NHC(O)R⁴, wherein R⁴ is a hydrocarbon having between 1 and 50 carbon atoms.

Claim 12 (original): An inhibitor according to claim 11 where R¹ is hydrogen; and R⁴ is a hydrocarbon having between 1 and 20 carbon atoms.

Claim 13 (original): An inhibitor according to claim 12 wherein R⁴ is a hydrocarbon having between 1 and 8 carbon atoms.

Claim 14 (original): An inhibitor according to claim 13 wherein R⁴ is methyl.

Claim 15 (original): An inhibitor according to claim 11 wherein R¹ is sulfate; and R⁴ is a hydrocarbon having between 1 and 20 carbon atoms.

Claim 16 (original): An inhibitor according to claim 15 wherein R⁴ is a hydrocarbon having between 1 and 8 carbon atoms.


Claim 17 (original): An inhibitor according to claim 16 wherein R⁴ is methyl.

Claim 18 (original): An inhibitor according to claim 11 wherein R¹ is methyl sulfate; and R⁴ is a hydrocarbon having between 1 and 20 carbon atoms.

Claim 19 (original): An inhibitor according to claim 18 where R⁴ is a hydrocarbon having between 1 and 8 carbon atoms.

Claim 20 (canceled)

Claim 21 (original): An inhibitor of hexoaminidase or glycosidase represented by the following structure:



Claim 22 (original): A process for inhibiting a catalytic activity of a hexoaminidase or glycosidase comprising the step of contacting the hexoaminidase or glycosidase with an inhibitor selected from claims 1, 11, and 21 of sufficient concentration for inhibiting said hexoaminidase or glycosidase.

Claim 23 (original): A process for treating a subject having arthritis comprising the step of administering an inhibitor selected from claims 1, 11, and 21 to said subject of sufficient quantity for inhibiting hexoaminidase activity within said patient.